Drugs / SB-756050
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00733577 | Aug 2008 → Mar 2009 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00607906 | Nov 2007 → Mar 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-756050 | “We report here the safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in patients with T2D.” PMID 27121782 ↗ May 2013 |
| Known as | SB-050 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303545 ↗ |
| Action | Activate | “a selective TGR5 agonist” PMID 27121782 ↗ May 2013 |
| Modality | Small molecule | — CHEMBL4303545 ↗ |
| Route | Oral | “Eligible subjects will receive oral immediate release capsules of SB-756050” NCT00607906 ↗ |